| 盐酸哌甲酯控释片治疗注意缺陷多动障碍研究进展 |
| |
| 引用本文： | 崔永华,郑毅. 盐酸哌甲酯控释片治疗注意缺陷多动障碍研究进展[J]. 中国新药杂志, 2006, 15(20): 1731-1734,1784 |
| |
| 作者姓名： | 崔永华 郑毅 |
| |
| 作者单位： | 首都医科大学附属北京安定医院十一区,北京,100088 |
| |
| 摘 要： | 注意缺陷多动障碍是一种儿童期常见的精神障碍，中枢兴奋剂如盐酸哌甲酯片是临床治疗此类障碍的一线药物。然而，由于盐酸哌甲酯片疗效持续时间较短，需要每天多次服药使治疗依从性不佳。盐酸哌甲酯控释片（专注达）是每天1次服用的渗透型控释片剂，成为治疗注意缺陷多动障碍的有价值药物。现综述其药动学、药理作用、剂型特点、临床疗效和安全性研究进展。
|
| 关 键 词： | 注意缺陷多动障碍 盐酸哌甲酯 控释制剂 |
| 文章编号： | 1003-3734（2006）20-1731-05 |
| 收稿时间： | 2006-10-10 |
| 修稿时间： | 2006-10-10 |
Treatment of children and adolescents with attention deficit/hyperactivity disorder with methylphenidate hydrochloride |
| |
| CUI Yong-hua,ZHENG Yi. Treatment of children and adolescents with attention deficit/hyperactivity disorder with methylphenidate hydrochloride[J]. Chinese Journal of New Drugs, 2006, 15(20): 1731-1734,1784 |
| |
| Authors: | CUI Yong-hua ZHENG Yi |
| |
| Affiliation: | Eleven Ward, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China |
| |
| Abstract: | Attention deficit/hyperactivity disorder (ADHD) is one of the most prevalent childhood psychiatric disorders. Stimulant medications are among the first-line agents in the pharmacotherapy of ADHD. Of the stimulant medications, methylphenidate ( MPH ) is the most studied. Compared with immediate-release (IR) MPH with a short duration of action requiring multiple daily dosing, which creates significant problems in the compliance of schools, parents/caregivers, and children, extended-release stimulant preparations have become a favorable pharmacological treatment for ADHD. OROS MPH (CONCERTA) is a once-daily, osmotic, controlled-release tablet of MPH. This review discussed the pharmacology, clinical effectiveness and safety of the controlled-release tablets of methylphenidate hydro-chloride. |
| |
| Keywords: | attention deficit/hyperactivity disorder (ADHD) methylphenidate hydrochloride delayed-action preparations |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
